Clinical Trial Update: Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants [Phase 2]

View source ↗

Summary

Phase 2 trial update examining single-agent niraparib and niraparib plus PD-1 inhibitors in non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Niraparib (Niraparib)
• niraparib plus PD-1 inhibitors

Snippet

Sponsor: Tesaro, Inc. | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2021-07-07